Department of Physics, Bogazici University, Istanbul 34342, Turkey
2.
Center for Life Sciences and Technologies, Bogazici University, Istanbul 34342, Turkey
3.
Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo 060-8648, Japan
Academic Editor: Xiaojun Tian
Received:
06 May 2022
Revised:
16 June 2022
Accepted:
29 June 2022
Published:
01 August 2022
Tumor hypoxia is commonly recognized as a condition stimulating the progress of the aggressive phenotype of tumor cells. Hypoxic tumor cells inhibit the delivery of cytotoxic drugs, causing hypoxic areas to receive insufficient amounts of anticancer agents, which results in adverse treatment responses. Being such an obstruction to conventional therapies for cancer, hypoxia might be considered a target to facilitate the efficacy of treatments in the resistive environment of tumor sites. In this regard, benefiting from prodrugs that selectively target hypoxic regions remains an effective approach. Additionally, combining hypoxia-activated prodrugs (HAPs) with conventional chemotherapeutic drugs has been used as a promising strategy to eradicate hypoxic cells. However, determining the appropriate sequencing and scheduling of the combination therapy is also of great importance in obtaining favorable results in anticancer therapy. Here, benefiting from a modeling approach, we study the efficacy of HAPs in combination with chemotherapeutic drugs on tumor growth and the treatment response. Different treatment schedules have been investigated to see the importance of determining the optimal schedule in combination therapy. The effectiveness of HAPs in varying hypoxic conditions has also been explored in the study. The model provides qualitative conclusions about the treatment response, as the maximal benefit is obtained from combination therapy with greater cell death for highly hypoxic tumors. It has also been observed that the antitumor effects of HAPs show a hypoxia-dependent profile.
Citation: Defne Yilmaz, Mert Tuzer, Mehmet Burcin Unlu. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach[J]. Mathematical Biosciences and Engineering, 2022, 19(11): 10941-10962. doi: 10.3934/mbe.2022511
Related Papers:
[1]
Fan He, Minru Li, Xinyu Wang, Lu Hua, Tingting Guo .
Numerical investigation of quantitative pulmonary pressure ratio in different degrees of stenosis. Mathematical Biosciences and Engineering, 2024, 21(2): 1806-1818.
doi: 10.3934/mbe.2024078
[2]
Zhenshuang Du, Qingwei Yang, Hefan He, Mingxia Qiu, Zhiyao Chen, Qingfu Hu, Qingmao Wang, Ziping Zhang, Qionghua Lin, Liuyue Huang, Yajiao Huang .
A comprehensive health classification model based on support vector machine for proseal laryngeal mask and tracheal catheter assessment in herniorrhaphy. Mathematical Biosciences and Engineering, 2020, 17(2): 1838-1854.
doi: 10.3934/mbe.2020097
[3]
K. Maqbool, S. Shaheen, A. M. Siddiqui .
Effect of nano-particles on MHD flow of tangent hyperbolic fluid in a ciliated tube: an application to fallopian tube. Mathematical Biosciences and Engineering, 2019, 16(4): 2927-2941.
doi: 10.3934/mbe.2019144
[4]
Urszula Ledzewicz, Behrooz Amini, Heinz Schättler .
Dynamics and control of a mathematical model for metronomic chemotherapy. Mathematical Biosciences and Engineering, 2015, 12(6): 1257-1275.
doi: 10.3934/mbe.2015.12.1257
[5]
Khaphetsi Joseph Mahasa, Rachid Ouifki, Amina Eladdadi, Lisette de Pillis .
A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept. Mathematical Biosciences and Engineering, 2022, 19(5): 4429-4457.
doi: 10.3934/mbe.2022205
[6]
Ruohan Li, Jinzhi Lei .
Optimal therapy schedule of chimeric antigen receptor (CAR) T cell immunotherapy. Mathematical Biosciences and Engineering, 2025, 22(7): 1653-1679.
doi: 10.3934/mbe.2025061
[7]
Yangjin Kim, Seongwon Lee, You-Sun Kim, Sean Lawler, Yong Song Gho, Yoon-Keun Kim, Hyung Ju Hwang .
Regulation of Th1/Th2 cells in asthma development: A mathematical model. Mathematical Biosciences and Engineering, 2013, 10(4): 1095-1133.
doi: 10.3934/mbe.2013.10.1095
[8]
Li Cai, Yu Hao, Pengfei Ma, Guangyu Zhu, Xiaoyu Luo, Hao Gao .
Fluid-structure interaction simulation of calcified aortic valve stenosis. Mathematical Biosciences and Engineering, 2022, 19(12): 13172-13192.
doi: 10.3934/mbe.2022616
[9]
Alexandre Cornet .
Mathematical modelling of cardiac pulse wave reflections due to arterial irregularities. Mathematical Biosciences and Engineering, 2018, 15(5): 1055-1076.
doi: 10.3934/mbe.2018047
[10]
B. Wiwatanapataphee, D. Poltem, Yong Hong Wu, Y. Lenbury .
Simulation of Pulsatile Flow of Blood in Stenosed Coronary Artery Bypass with Graft. Mathematical Biosciences and Engineering, 2006, 3(2): 371-383.
doi: 10.3934/mbe.2006.3.371
Abstract
Tumor hypoxia is commonly recognized as a condition stimulating the progress of the aggressive phenotype of tumor cells. Hypoxic tumor cells inhibit the delivery of cytotoxic drugs, causing hypoxic areas to receive insufficient amounts of anticancer agents, which results in adverse treatment responses. Being such an obstruction to conventional therapies for cancer, hypoxia might be considered a target to facilitate the efficacy of treatments in the resistive environment of tumor sites. In this regard, benefiting from prodrugs that selectively target hypoxic regions remains an effective approach. Additionally, combining hypoxia-activated prodrugs (HAPs) with conventional chemotherapeutic drugs has been used as a promising strategy to eradicate hypoxic cells. However, determining the appropriate sequencing and scheduling of the combination therapy is also of great importance in obtaining favorable results in anticancer therapy. Here, benefiting from a modeling approach, we study the efficacy of HAPs in combination with chemotherapeutic drugs on tumor growth and the treatment response. Different treatment schedules have been investigated to see the importance of determining the optimal schedule in combination therapy. The effectiveness of HAPs in varying hypoxic conditions has also been explored in the study. The model provides qualitative conclusions about the treatment response, as the maximal benefit is obtained from combination therapy with greater cell death for highly hypoxic tumors. It has also been observed that the antitumor effects of HAPs show a hypoxia-dependent profile.
1.
Introduction
Benign airway stenosis refers to airway stenosis caused by airway wall damage by a variety of non-neoplastic diseases, which can lead to cough, sputum, varying degrees of dyspnea and other symptoms. Benign airway stenosis seriously affects the quality of life of patients, and even the occurrence of respiratory failure and death. The etiology includes: long-term tracheal intubation, tracheotomy, tracheal-bronchial tuberculosis, trauma and so on [1]. Previous treatment of secondary benign airway stenosis was limited, mainly based on surgical resection and reconstruction. However, surgical treatment not only requires good condition of patients, but also has many disadvantages, such as many perioperative complications and long recovery time after operation. In particular, those patients are often suffering from combined pulmonary infection, dysfunction of central nervous system and other complications, consequently leading to the loss of possibility for traditional surgical procedures. With the rapid development of interventional therapy under bronchoscopy, the endoscopic interventional therapy is becoming more and more [2], such as laser, balloon dilatation, freezing, stenting and so on. These measures provide safer and more effective treatment options for patients with benign airway stenosis after tracheotomy. Among them, Montgomery T-tube implantation under rigid bronchoscopy is considered as an effective, safe and well-tolerated method for tracheal stenosis.
2.
Patients and methods
This study retrospectively reviewed 20 patients who had treatments of secondary benign airway stenosis after tracheotomy with Montgomery T-tube between September 2015 and February 2019 in Sir Run Run Shaw Hospital, affiliated with Zhejiang University. The clinical data including clinical features, efficacy, complications and prognosis were retrospectively analyzed to evaluate the value of Montgomery T-tube placement in secondary benign airway stenosis after tracheotomy.
All of the 20 patients were hospitalized, including 14 males and 6 females aged 20–71 years old. The clinical manifestations were mainly cough, sputum, varying degrees of dyspnea, and failed plugging with tracheostomy cannula. The duration of tracheotomy was 28 days to 16 months (Table 1). Twenty patients were diagnosed with benign tracheal stenosis by medical history, physical examination, and chest CT scan and bronchoscopy. Complete trachea obstruction was in 8 cases and partial tracheal stenosis was in 12 cases. After discussion, the intervention team decided that these patients were not suitable for surgical tracheal resection and reconstruction. Through the multidisciplinary (anesthesiology, ENT and cardiothoracic surgery) discussion, a suitable endoscopic interventional treatment was developed.
Table 1.
Basic information of patients.
N
G
Age
Underlying diseases
Duration of tracheotomy
Clinical symptoms
The degree of stenosis
Stenosis types
Stenosis length
1
M
71
Cerebral hemorrhage
1 month
Failed tracheal plugging
> 2/3
Granulation tissue combined with tracheal wall collapse
The protocol of endoscopic intervention is as follows:
a. Anesthesia: Patients were given tracheotomy and indwelling metal tracheostomy cannulas before operation. After intravenous anesthesia, the metal tracheostomy cannula was replaced by a plastic tracheostomy cannula and then connected to a ventilator.
b. Airway assessment and intervention: Oral insertion of STORZ rigid bronchoscope was performed after position placed to observe the stenosis of glottic and airway. For patients with incomplete airway atresia, rigid bronchoscopic mechanical expansion, balloon dilatation, granulation tissue resection or other intervention methods can be used to dilatation the narrow airway to 10–15 mm, hence ensuring that the airway has adequate space for T-tube placement. For patients with complete airway obstruction (8/20, Figure 1), tracheostomy cannulas were replaced with size 5.5–6 tracheal tubes for ventilation. After the ENT physician's cooperation, the anatomical structure through retrograde exploration from the distal end of atresia trachea was undertaken, and electric knife or laser was used in the proximal end of trachea for airway atresia recanalization. Balloon dilatation of the stenotic trachea was then performed after successful recanalization.
Figure 1.
The bronchoscopic result indicated the complete atresia of upper trachea (A). The CT result suggested the complete atresia of cervical trachea (B). Complete atresia of cervical trachea and indwelling metal tracheostomy cannula were found before the operation (C). Airway atresia recanalization was achieved and the indwelling T-tube was observed after the operation (D).
c. T-tube placement: T-tubes with appropriate diameter were selected according to the chest CT measurement results, and then were pruned and polished when the length of T-tube proximal and distal branch was determined by bronchoscopic labeling and measurement (Table 2). The distal branch of T-tube was clamped by a vessel forceps and inserted into the airway, and the proximal branch was pulled into the proximal airway by foreign body forceps through the rigid bronchial duct, and then the position was adjusted.
Table 2.
Information of Montgomery T-tube implantation.
Cases
Rate
T-tube model (diameter mm)
13 mm: 3 14 mm: 5 15 mm: 3
8/20 9/20 3/20
Combined with balloon dilatation
18
18/20
Combined with rigid bronchoscopic mechanical expansion
d. Off-line recovery and care: The external branch of T-tube was closed, and the laryngeal mask was inserted for ventilation. The patients can be taken off the ventilator and returned back ward after spontaneous breathing was restored. 18 patients restored oral ventilation in the recovery room; 2 patient was unable restore oral ventilation and was failed in tracheal plugging; blood oxygen saturation decreased in 2 patients after returning to the ward, which was ameliorated by opening the external branches of T-tubes; tracheal plugging was successful after 24 hours, and the possible vocal cord edema was observed as a considerably postoperative complication. The routine doctor's advice includes: reducing mucous (ambroxol), atomization (saline + ipratropium bromide), the use of prophylactic antibiotics, cervical and chest CT review 3 days after operation; the patients were admitted to hospital for assessments respectively at 1, 3 and 6 months after the operation.
3.
Results
Eighteen patients successfully restored oral respiration after closing external branches of T-tubes, and were able to phonate with significant improvement in quality of life. CPAP-assisted ventilation was performed after the surgery in 1 patient due to the combined OSAS (sleep apnea syndrome). One patient still failed to restore oral breathing after the operation, considering as bilateral vocal cord paralysis caused by cerebrovascular accident after ENT assessment. And another patient failed was due to pulmonary infection. Mild mediastinal emphysema in mediastinum and neck was observed in 1 patient in routine examination of chest CT after the operation, which was self-absorbed after oxygen inhalation (Figure 2); different levels of increased sputum were found in all 20 patients; obstruction in partial lumen due to phlegm scab formation was found in only 4 cases by bronchoscopy, which was extracted by repeatedly douching of normal saline. Granulation tissue formation on the edge of T-tubes was found in 13 patients at 3 and 6 months respectively after the operation (Figure 3), and granulation tissue resection was then performed in 5 cases among them. Increases in cough and expectoration were found in 1 patient with cerebral infarction at 1 month after the operation; no fever was observed; the chest CT result indicated the right lower lung infection, considering as aspiration pneumonia, which was improved after anti-infection treatment. Dyspnea appeared in 1 patient at 15 days after the operation, and then ventilation by opening external branches of T-tubes was performed; the neck and chest CT examination showed that the T-tube moves down about 1 cm due to the large incision stoma in the patient, consequently leading to stenosis in the upper edge of T-tube caused by the shorter length of superior T-tube branch. Thus, T-tube replacement was scheduled to perform by a bronchoscope under general anesthesia, and partial of the incision stoma was sutured to prevent T-tube displacement. Two patients accepted the T-tube re-implantation due to the re-stenosis after removing the T-tube (Table 3).
Figure 2.
Postoperative neck and subcutaneous emphysema, which was self-absorbed after oxygen inhalation.
Figure 3.
Granulation tissue formed on the upper limb of the tube and secondary airway stenosis (A); Airway stenosis was improved after endoscopic granulation tissue resection (B).
Ten patients were successfully removed T-tubes about 6 months after the operation, and no dyspnea or other uncomfortable symptoms was observed after T-tube removal. However, 2 patients replaced the T-tube. The remaining 8 patients have still been indwelling of T-tubes and following up.
4.
Discussion
The incidence of secondary benign airway stenosis caused by long-term tracheal intubation and tracheotomy was rare previously. As reported, the incidence of benign airway stenosis in the critically ill patients with ICU mechanical ventilation was reported to be about 1% [3]. However, with the improvement of surgical operation and critical medicine at present, the incidence of benign tracheal stenosis is underestimated. Previous treatments of secondary benign airway stenosis were mainly based on curative surgical resection and reconstruction [4]. However, whether the operation can be performed is highly related to the degree and range of airway stenosis, the presence of infection and other factors. Besides, surgical treatment also requires patients in good condition and can tolerate surgery. However, these patients tend to have more complications, for examples, most of the 20 patients in this study have traumatic brain injury, cerebrovascular accident and other severe central nervous system injury, which do not allow the patients to tolerate surgical treatment after assessments. Moreover, there are many problems such as large surgical trauma, many perioperative complications and difficult operation, and even occurrence of long-term anastomotic restenosis in a considerable ratio [5]. Although the surgical treatment, when not contraindicated by associated diseases or by the excessive length of the tracheal lesions, still remains the treatment of choice, with the development of interventional therapy, endoscopic interventional therapy has become an effective and feasible method for treatment of benign tracheobronchial stenosis because of its limited trauma, easy operation and rapid relief of symptoms.
In 1965, William Montgomery pioneered the use of T-tube for the prevention of tracheal stenosis after tracheal surgery [6]. The original T-tube was made of acrylic material and was later changed to silicone material due to the hard texture. The internal branch of the T-tube is used to support and shape trachea, and the external branch is used for external fixation, preventing T-tube slippage and displacement. There are different diameter models in internal branch of T-tube, which can be chosen according to the tracheal thickness of patients. The operating doctor can determine the length of upper and lower branches according to the length of tracheal stenosis and the location of incision. This should be carefully measured and evaluated before T-tube placement. The advantages of the T-tube in treatment of benign airway stenosis are as follows:
a. Patients can restore natural cavity breathing and phonate after T-tube placement.
b. T-tube is made by silicone material which is soft and has considerably less irritation to airway, and not easy to produce granulation tissue compared with metal material [7,8]; patients are well tolerated with T-tube which is good for supporting and conducive to airway remodeling.
c. The external branch of T-tube plays a fixed role and overcomes the disadvantage that the straight cylinder type silicone stent is easy to shift. It has been reported that stent displacement occurs in approximately 6–18% of patients with the most frequently used straight cylinder type silicone DUMON stent [9,10].
d. If stenosis of the upper end of T-tube or blockage due to secretions in T-tube appears again, the doctor can open the external branch of T-tube to conduct ventilation and mucous suction through the external branch which can connect to a ventilator. DUMON stent is more likely to result in accumulation and blockage of mucous, and there is no effective way to avoid. If necessary, DUMON stent must be removed. T-tube has obviously better safety compared with DUMON stent and metal stent.
e. T-tube is easy to place and remove, and the support time of T-tube usually takes at least 6 months. Compared with silicone stent, metal stent is not easy to remove [7,11]. Therefore, for subglottic benign airway stenosis, the Montgomery T-tube is a better choice compared with traditional self-expanding metal stent and straight cylinder silicone DUMON stent.
In this study, 20 cases of T-tube placement were under general anesthesia, which is more conducive to implementation of the operation [12,13]. A tracheostomy cannula was placed before T-tube placement to ensure safe ventilation and operation. Among them, 8 patients had complete airway obstruction and required retrograde exploration of the distal end of atresia airway by surgical teamwork; besides, electrocoagulation was performed for airway recanalization. These patients need more sufficient assessments and teamwork before operation, and should be carefully operated to avoid tracheal perforation, fracture, tracheo-esophageal fistula and other complications. All patients were operated under rigid bronchoscopy, which is easier and safer for balloon dilatation, granulation excision or other operation of airway before T-tube implantation. After placing T-tube in incision stoma, it needs to be adjusted under rigid bronchoscopy [14].
The most important point for T-tube implantation is preoperative evaluation. The achievement rate of T-tube placement is closely related to the location and length of stenosis. Therefore, the range and severity of airway stenosis, as well as the distance from stenosis area to glottis and carina should be evaluated by imaging examination before operation. The major points are as follows:
a. The upper branch of T-tube cannot be longer than the glottis, or else it will result in glottis discomfort and dysfunction; the distance from the upper end of T-tube to glottis is at least 1 cm, so that patient with the distance from narrow segment to glottis shorter than 2 cm is not suitable for T-tube placement.
b. The diameter of T-tube should be appropriate, otherwise, it will cause the risk of granulation tissue on the edge of T-tube. Besides, the compressed and ischemic airway mucosa is also easy to combine with infection and restenosis. The diameter of T-tube should not be too small, or it will cause mucous obstruction and is not easy for airway support.
c. There is a function of the structure of tracheal cartilage. If the cartilage collapse and lose support function completely, the patient is not suitable for T-tube implantation.
The success rate and safety of T-tube placement were higher, similar as those in previously reports [15,16,17]. All of the 20 patients were successfully placed T-tubes. Although 2 patients failed in T-tubes plugging in 24h after operation, they were successfully completely plugged several days. We attributed the delay of T-tube plugging to the adaptation and condition of the patients. We found that the short-term complications mainly included mucous secretion, irritating cough, and transient dyspnea, which were generally alleviated after symptomatic treatments alone; while long-term complication was mainly granulation tissue hyperplasia on the edge of T-tube, and only 5 patients needed for endoscopic resection of granulation tissue due to secondary airway stenosis. Since many patients suffer from sputum retention and require long-time T-tube implantation, attention and assessments of expectoration in patients should be considered after operation, and regular cleaning of the wall is necessary to prevent T-tubes from occlusion. For benign airway stenosis, support time of T-tube has not been determined yet [12,18]. The removal time should be determined based on the characteristics of each patient's condition, and performed at 6 months after the operation is generally appropriate. After T-tube removal, a temporary tracheostomy cannula should be placed, which can be removed if there is no airway collapse at 2 months after the operation. Otherwise, T-tube replacement or surgical treatment should be selected. There are 3 cases re-implanted the T-tube. One patient re-implanted due to the moving down of T-tube, another two patients re-implanted due to re-stenosis after T-tube removal (3 months and another 2 months later). For those two patients, treatment should in fact be based on a combination of surgical and endoscopic treatments, and also remind us that T-tubes may be effective and safe, however, surgical treatment still is an important choice. The target group of T-tube implantation should be careful and precise, exclude those patients who eligible for surgery.
5.
Conclusions
In summary, for patients with secondary benign airway stenosis after tracheal intubation or tracheostomy who are not suitable for surgery, Montgomery T-tube replacement under rigid bronchoscopy is an effective, safe and well-tolerated method for tracheal stenosis, and is helpful for improvement of quality of life.
Acknowledgements
The study was supported by Zhejiang Medical and Health Science and Technology Project (no. 2016ZDA010).
Conflict of interest
The authors declare no conflict of interest.
References
[1]
P. Vaupel, A. Mayer, Hypoxia in cancer: significance and impact on clinical outcome, Cancer Metastasis Rev., 26 (2007), 225–239. https://doi.org/10.1007/s10555-007-9055-1 doi: 10.1007/s10555-007-9055-1
[2]
C. T. Lee, M. K. Boss, M. W. Dewhirst, Imaging tumor hypoxia to advance radiation oncology, Antioxid. Redox Signaling, 21 (2014), 313–337. https://doi.org/10.1089/ars.2013.5759 doi: 10.1089/ars.2013.5759
[3]
M. R. Horsman, J. Overgaard, The impact of hypoxia and its modification of the outcome of radiotherapy, J. Radiat. Res., 57 (2016), i90–i98. https://doi.org/10.1093/jrr/rrw007 doi: 10.1093/jrr/rrw007
[4]
J. A. Forsythe, B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, et al., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol. Cell. Biol., 16 (1996), 4604–4613. https://doi.org/10.1128/MCB.16.9.4604 doi: 10.1128/MCB.16.9.4604
[5]
A. Ahluwalia, A. S Tarnawski, Critical role of hypoxia sensor-hif-1α in vegf gene activation. implications for angiogenesis and tissue injury healing, Curr. Med. Chem., 19 (2012), 90–97. https://doi.org/10.2174/092986712803413944 doi: 10.2174/092986712803413944
[6]
E. K. Rofstad, Microenvironment-induced cancer metastasis, Int. J. Radiat. Biol., 76 (2000), 589–605. https://doi.org/10.1080/095530000138259 doi: 10.1080/095530000138259
[7]
M. G. Binker, A. A. Binker-Cosen, D. Richards, H. Y. Gaisano, R. H. de Cosen, L. I. Cosen-Binker, Hypoxia–reoxygenation increase invasiveness of panc-1 cells through rac1/mmp-2, Biochem. Biophys. Res. Commun., 393 (2010), 371–376. https://doi.org/10.1016/j.bbrc.2010.01.125 doi: 10.1016/j.bbrc.2010.01.125
[8]
R. M. Phillips, Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs, Cancer Chemother. Pharmacol., 77 (2016), 441–457. https://doi.org/10.1007/s00280-015-2920-7 doi: 10.1007/s00280-015-2920-7
[9]
W. A. Denny, The role of hypoxia-activated prodrugs in cancer therapy, Lancet Oncol., 1 (2000), 25–29. https://doi.org/10.1016/S1470-2045(00)00006-1 doi: 10.1016/S1470-2045(00)00006-1
[10]
S. G. Peeters, C. M. Zegers, R. Biemans, N. G. Lieuwes, R. G. van Stiphout, A. Yaromina, et al., TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18f] hx4 hypoxia pet imaging, Clin. Cancer Res., 21 (2015), 2984–2992. https://doi.org/10.1158/1078-0432.CCR-15-0018 doi: 10.1158/1078-0432.CCR-15-0018
[11]
V. Liapis, A. Labrinidis, I. Zinonos, S. Hay, V. Ponomarev, V. Panagopoulos, et al., Hypoxia-activated pro-drug th-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma, Cancer Lett., 357 (2015), 160–169. https://doi.org/10.1016/j.canlet.2014.11.020 doi: 10.1016/j.canlet.2014.11.020
[12]
Q. Liu, J. D. Sun, J. Wang, D. Ahluwalia, A. F. Baker, L. D. Cranmer, et al., TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules, Cancer Chemother. Pharmacol., 69 (2012), 1487–1498. https://doi.org/10.1007/s00280-012-1852-8 doi: 10.1007/s00280-012-1852-8
[13]
Hypoxia/Normoxia, in Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine, Springer, Berlin, Heidelberg, (2006), 853–853. https://doi.org/10.1007/3-540-29623-9_7440
[14]
C. Wigerup, S. Påhlman, D. Bexell, Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer, Pharmacol. Ther., 164 (2016), 152–169. https://doi.org/10.1016/j.pharmthera.2016.04.009 doi: 10.1016/j.pharmthera.2016.04.009
[15]
J. D. Sun, Q. Liu, J. Wang, D. Ahluwalia, D. Ferraro, Y. Wang, et al., Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer, Clin. Cancer Res., 18 (2012), 758–770. https://doi.org/10.1158/1078-0432.CCR-11-1980 doi: 10.1158/1078-0432.CCR-11-1980
[16]
F. Meng, J. W. Evans, D. Bhupathi, M. Banica, L. Lan, G. Lorente, et al., Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302, Mol. Cancer Ther., 11 (2012), 740–751. https://doi.org/10.1158/1535-7163.MCT-11-0634 doi: 10.1158/1535-7163.MCT-11-0634
[17]
Y. Huang, Y. Tian, Y. Zhao, C. Xue, J. Zhan, L. Liu, et al., Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo, Cancer Commun., 38 (2018), 1–9. https://doi.org/10.1186/s40880-018-0285-0 doi: 10.1186/s40880-018-0285-0
[18]
G. J. Weiss, J. R. Infante, E. G. Chiorean, M. J. Borad, J. C. Bendell, J. R. Molina, et al., Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies, Clin. Cancer Res., 17 (2011), 2997–3004. https://doi.org/10.1158/1078-0432.CCR-10-3425 doi: 10.1158/1078-0432.CCR-10-3425
[19]
I. Lohse, J. Rasowski, P. Cao, M. Pintilie, T. Do, M. S. Tsao, et al., Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug th-302, Oncotarget, 7 (2016), 33571. https://doi.org/10.18632/oncotarget.9654 doi: 10.18632/oncotarget.9654
[20]
S. Matsumoto, S. Kishimoto, K. Saito, Y. Takakusagi, J. P. Munasinghe, N. Devasahayam, et al., Metabolic and physiologic imaging biomarkers of the tumor microenvironment predict treatment outcome with radiation or a hypoxia-activated prodrug in mice, Cancer Res., 78 (2018), 3783–3792. https://doi.org/10.1158/0008-5472.CAN-18-0491 doi: 10.1158/0008-5472.CAN-18-0491
[21]
K. J. Nytko, I. Grgic, S. Bender, J. Ott, M. Guckenberger, O. Riesterer et al., The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy, Oncotarget, 8 (2017), 23702. https://doi.org/10.18632/oncotarget.15784 doi: 10.18632/oncotarget.15784
[22]
J. K. Saggar, I. F. Tannock, Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy, Int. J. Cancer, 134 (2014), 2726–2734. https://doi.org/10.1002/ijc.28595 doi: 10.1002/ijc.28595
[23]
V. Liapis, I. Zinonos, A. Labrinidis, S. Hay, V. Ponomarev, V. Panagopoulos, et al., Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (th-302) in osteolytic breast cancer murine models, Cancer Med., 5 (2016), 534–545. https://doi.org/10.1002/cam4.599 doi: 10.1002/cam4.599
[24]
J. K. Saggar, I. F. Tannock, Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation–-an effect that is inhibited by the hypoxia-activated prodrug TH-302, Clin. Cancer Res., 21 (2015), 2107–2114. https://doi.org/10.1158/1078-0432.CCR-14-2298 doi: 10.1158/1078-0432.CCR-14-2298
[25]
J. D. Sun, Q. Liu, D. Ahluwalia, W. Li, F. Meng, Y. Wang, et al., Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer, Cancer Biol. Ther., 16 (2015), 438–449. https://doi.org/10.1080/15384047.2014.1003005 doi: 10.1080/15384047.2014.1003005
[26]
S. P. Chawla, L. D. Cranmer, B. A. Van Tine, D. R. Reed, S. H. Okuno, J. E. Butrynski, et al., Phase ii study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma, J. Clin. Oncol., 32 (2014), 3299. https://doi.org/10.1200/JCO.2013.54.3660 doi: 10.1200/JCO.2013.54.3660
[27]
K. N. Ganjoo, L. D. Cranmer, J. E. Butrynski, D. Rushing, D. Adkins, S. H. Okuno, et al., A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug th-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma, Oncology, 80 (2011), 50–56. https://doi.org/10.1159/000327739 doi: 10.1159/000327739
[28]
J. Von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, et al., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international catapult I study group, J. Clin. Oncol., 18 (2000), 1351–1359. https://doi.org/10.1200/JCO.2000.18.6.1351 doi: 10.1200/JCO.2000.18.6.1351
[29]
F. W. Hunter, B. G. Wouters, W. R. Wilson, Hypoxia-activated prodrugs: paths forward in the era of personalised medicine, Br. J. Cancer, 114 (2016), 1071–1077. https://doi.org/10.1038/bjc.2016.79 doi: 10.1038/bjc.2016.79
[30]
J. Sun, Q. Liu, D. Ahluwalia, J. Curd, M. Matteucci, C. Hart, Complementary chemotherapies with th-302, a novel hypoxia activated prodrug: optimization of dosing regimens and schedules for study in phase 1/2 with docetaxel, gemcitabine, pemetrexed, and doxorubicin, Biosymposia: Hypoxia, Ischemia, Inflammation, 2008.
[31]
S. B. Reddy, S. K. Williamson, Tirapazamine: a novel agent targeting hypoxic tumor cells, Expert Opin. Invest. Drugs, 18 (2009), 77–87. https://doi.org/10.1517/13543780802567250 doi: 10.1517/13543780802567250
[32]
J. C. Forster, L. G. Marcu, E. Bezak, Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation, Physica Med., 64 (2019), 145–156. https://doi.org/10.1016/j.ejmp.2019.07.006 doi: 10.1016/j.ejmp.2019.07.006
[33]
W. Tuckwell, E. Bezak, E. Yeoh, L. Marcu, Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer, Phys. Med. Biol., 53 (2008), 4489. https://doi.org/10.1088/0031-9155/53/17/002 doi: 10.1088/0031-9155/53/17/002
[34]
W. M. Harriss-Phillips, E. Bezak, E. Yeoh, Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer, Br. J. Radiol., 84 (2011), 903–918. https://doi.org/10.1259/bjr/25012212 doi: 10.1259/bjr/25012212
[35]
W. M. Harriss-Phillips, E. Bezak, A. Potter, Stochastic predictions of cell kill during stereotactic ablative radiation therapy: Do hypoxia and reoxygenation really matter?, Int. J. Radiat. Oncol. Biol. Phys., 95 (2016), 1290–1297. https://doi.org/10.1016/j.ijrobp.2016.03.014 doi: 10.1016/j.ijrobp.2016.03.014
[36]
L. G. Marcu, D. Marcu, S. M. Filip, In silico study of the impact of cancer stem cell dynamics and radiobiological hypoxia on tumour response to hyperfractionated radiotherapy, Cell proliferation, 49 (2016), 304–314.
[37]
E. Lindblom, I. Toma-Dasu, A. Dasu, Accounting for two forms of hypoxia for predicting tumour control probability in radiotherapy: An in silico study, in Oxygen Transport to Tissue XL. Advances in Experimental Medicine and Biology, 1072 (2018), 183–187. https://doi.org/10.1007/978-3-319-91287-5_29
[38]
A. Foehrenbacher, K. Patel, M. Abbattista, C. P. Guise, T. W. Secomb, W. R. Wilson, et al., The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug pr-104, Frontiers in oncology, 3 (2013), 263. https://doi.org/10.3389/fonc.2013.00263 doi: 10.3389/fonc.2013.00263
[39]
A. B. Foehrenbacher, T. W. Secomb, W. R. Wilson, K. O. Hicks, Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling, Front. Oncol., 3 (2013), 314. https://doi.org/10.3389/fonc.2013.00314 doi: 10.3389/fonc.2013.00314
[40]
K. O. Hicks, F. B. Pruijn, T. W. Secomb, M. P. Hay, R. Hsu, J. M. Brown, et al., Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs, J. Nat. Cancer Inst., 98 (2006), 1118–1128. https://doi.org/10.1093/jnci/djj306 doi: 10.1093/jnci/djj306
[41]
C. Meaney, G. G. Powathil, A. Yaromina, L. J. Dubois, P. Lambin, M. Kohandel, Role of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach, Math. Biosci. Eng., 16 (2019), 6257. https://doi.org/10.3934/mbe.2019312 doi: 10.3934/mbe.2019312
[42]
C. Meaney, S. Rhebergen, M. Kohandel, In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery, PLoS Comput. Biol., 16 (2020), e1007926. https://doi.org/10.1371/journal.pcbi.1007926 doi: 10.1371/journal.pcbi.1007926
[43]
S. Hamis, M. Kohandel, L. J. Dubois, A. Yaromina, P. Lambin, G. G. Powathil, Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape, PLoS Comput. Biol., 16 (2020), e1008041. https://doi.org/10.1371/journal.pcbi.1008041 doi: 10.1371/journal.pcbi.1008041
[44]
X. Mao, S. McManaway, J. K. Jaiswal, P. B. Patel, W. R. Wilson, K. O. Hicks, et al., An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug sn30000 in multicellular tumour spheroids, PLoS Comput. Biol., 14 (2018), e1006469. https://doi.org/10.1371/journal.pcbi.1006469 doi: 10.1371/journal.pcbi.1006469
[45]
C. R. Hong, S. Y. Mehta, H. Liyanage, S. P. McManaway, H. H. Lee, J. K. Jaiswal, et al., Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug, Cancer Chemother. Pharmacol., 88 (2021), 673–687. https://doi.org/10.1007/s00280-021-04320-3 doi: 10.1007/s00280-021-04320-3
[46]
K. O. Hicks, B. G. Siim, J. K. Jaiswal, F. B. Pruijn, A. M. Fraser, R. Patel, et al., Pharmacokinetic/pharmacodynamic modeling identifies sn30000 and sn29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors, Clin. Cancer Res., 16 (2010), 4946–4957. https://doi.org/10.1158/1078-0432.CCR-10-1439 doi: 10.1158/1078-0432.CCR-10-1439
[47]
C. R. Hong, W. R. Wilson, K. O. Hicks, An intratumor pharmacokinetic/pharmacodynamic model for the hypoxia-activated prodrug evofosfamide (TH-302): Monotherapy activity is not dependent on a bystander effect, Neoplasia, 21 (2019), 159–171. https://doi.org/10.1016/j.neo.2018.11.009 doi: 10.1016/j.neo.2018.11.009
[48]
C. R. Hong, G. Bogle, J. Wang, K. Patel, F. B. Pruijn, W. R. Wilson, et al., Bystander effects of hypoxia-activated prodrugs: agent-based modeling using three dimensional cell cultures, Front. Pharmacol., 9 (2018), 1013. https://doi.org/10.3389/fphar.2018.01013 doi: 10.3389/fphar.2018.01013
[49]
D. Lindsay, C. M. Garvey, S. M. Mumenthaler, J. Foo, Leveraging hypoxia-activated prodrugs to prevent drug resistance in solid tumors, PLoS Comput. Biol., 12 (2016), e1005077. https://doi.org/10.1371/journal.pcbi.1005077 doi: 10.1371/journal.pcbi.1005077
[50]
S. Yonucu, D. Yilmaz, C. Phipps, M. B. Unlu, M. Kohandel, Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy, PLoS Comput. Biol., 13 (2017), 1–17, https://doi.org/10.1371/journal.pcbi.1005724 doi: 10.1371/journal.pcbi.1005724
[51]
M. Kohandel, M. Kardar, M. Milosevic, S. Sivaloganathan, Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies, Phys. Med. Biol., 52 (2007), 3665. https://doi.org/10.1088/0031-9155/52/13/001 doi: 10.1088/0031-9155/52/13/001
[52]
G. Powathil, M. Kohandel, S. Sivaloganathan, A. Oza, M. Milosevic, Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy, Phys. Med. Biol., 52 (2007), 3291. https://doi.org/10.1088/0031-9155/52/11/023 doi: 10.1088/0031-9155/52/11/023
[53]
E. Dalah, D. Bradley, A. Nisbet, A mathematical approach towards simulating a realistic tissue activity curve of 64Cu-ATSM for the purpose of sub-target volume delineation in radiotherapy, Nucl. Instrum. Methods Phys. Res., Sect. A, 619 (2010), 283–286. https://doi.org/10.1016/j.nima.2009.10.160 doi: 10.1016/j.nima.2009.10.160
[54]
E. Dalah, D. Bradley, A. Nisbet, Simulation of tissue activity curves of 64Cu-ATSM for sub-target volume delineation in radiotherapy, Phys. Med. Biol., 55 (2010), 681.
[55]
F. Winkler, S. V. Kozin, R. T. Tong, S. S. Chae, M. F. Booth, I. Garkavtsev, et al., Kinetics of vascular normalization by vegfr2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases, Cancer Cell, 6 (2004), 553–563. https://doi.org/10.1016/j.ccr.2004.10.011 doi: 10.1016/j.ccr.2004.10.011
[56]
W. R. Wilson, M. P. Hay, Targeting hypoxia in cancer therapy, Nat. Rev. Cancer, 11 (2011), 393–410. https://doi.org/10.1038/nrc3064 doi: 10.1038/nrc3064
[57]
L. J. Nugent, R. K. Jain, Extravascular diffusion in normal and neoplastic tissues, Cancer Res., 44 (1984), 238–244.
[58]
R. K. Jain, Transport of molecules in the tumor interstitium: a review, Cancer Res., 47 (1987), 3039–3051.
[59]
L. S. Goodman, Goodman and Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill New York, 1549 (1996).
[60]
K. M. Laginha, S. Verwoert, G. J. Charrois, T. M. Allen, Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors, Clin. Cancer Res., 11 (2005), 6944–6949. https://doi.org/10.1158/1078-0432.CCR-05-0343 doi: 10.1158/1078-0432.CCR-05-0343
[61]
A. W. El-Kareh, T. W. Secomb, A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells, Neoplasia, 2 (2000), 325.
[62]
A. J. Leu, D. A. Berk, A. Lymboussaki, K. Alitalo, R. K. Jain, Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation, Cancer Res., 60 (2000), 4324–4327.
[63]
M. Wu, H. B. Frieboes, S. R. McDougall, M. A. Chaplain, V. Cristini, J. Lowengrub, The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems, J. Theor. Biol., 320 (2013), 131–151. https://doi.org/10.1016/j.jtbi.2012.11.031 doi: 10.1016/j.jtbi.2012.11.031
[64]
G. Powathil, M. Kohandel, M. Milosevic, S. Sivaloganathan, Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies, Comput. Math. Methods Med., 2012 (2012). https: //doi.org/10.1155/2012/410602
[65]
A. S. Fung, J. Jonkman, I. F. Tannock, Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel, Neoplasia, 14 (2012), 324–IN6. https://doi.org/10.1593/neo.12346 doi: 10.1593/neo.12346
[66]
X. Mao, S. McManaway, J. K. Jaiswal, C. R. Hong, W. R. Wilson, K. O. Hicks, Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug sn30000, Cancer Biol. Ther., 20 (2019), 1258–1269. https://doi.org/10.1080/15384047.2019.1617570 doi: 10.1080/15384047.2019.1617570
[67]
S. Harris, P. Mistry, C. Freathy, J. Brown, P. Charlton, Antitumour activity of xr5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines, Br. J. Cancer, 92 (2005), 722–728. https://doi.org/10.1038/sj.bjc.6602403 doi: 10.1038/sj.bjc.6602403
[68]
J. M. Saucier, J. Yu, A. Gaikwad, R. L. Coleman, J. K. Wolf, J. A. Smith, Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model, J. Oncol. Pharm. Pract., 13 (2007), 39–45. https://doi.org/10.1177/1078155207077948 doi: 10.1177/1078155207077948
[69]
M. R. Horsman, L. S. Mortensen, J. B. Petersen, M. Busk, J. Overgaard, Imaging hypoxia to improve radiotherapy outcome, Nat. Rev. Clin. Oncol., 9 (2012), 674–687. https://doi.org/10.1038/nrclinonc.2012.171 doi: 10.1038/nrclinonc.2012.171
[70]
J. Overgaard, Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck–a systematic review and meta-analysis, Radiother. Oncol., 100 (2011), 22–32.
[71]
M. Kovacs, D. Hocking, J. Evans, B. Siim, B. Wouters, J. Brown, Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin, Br. J. Cancer, 80 (1999), 1245–1251. https://doi.org/10.1038/sj.bjc.6690492 doi: 10.1038/sj.bjc.6690492
[72]
X. Zhang, J. W. Wojtkowiak, G. V. Martinez, H. H. Cornnell, C. P. Hart, A. F. Baker, et al., Mr imaging biomarkers to monitor early response to hypoxia-activated prodrug TH-302 in pancreatic cancer xenografts, PloS One, 11 (2016), e0155289. https://doi.org/10.1371/journal.pone.0155289 doi: 10.1371/journal.pone.0155289
[73]
J. Cárdenas-Rodríguez, Y. Li, J. P. Galons, H. Cornnell, R. J. Gillies, M. D. Pagel, et al., Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the miapaca2 flank xenograft model, Magn. Reson. Imaging, 30 (2012), 1002–1009. https://doi.org/10.1016/j.mri.2012.02.015 doi: 10.1016/j.mri.2012.02.015
[74]
A. Leimgruber, K. Hickson, S. T. Lee, H. K. Gan, L. M. Cher, J. I. Sachinidis, et al., Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse, Eur. J. Nucl. Med. Mol. Imaging, 47 (2020), 1476–1485. https://doi.org/10.1007/s00259-020-04706-0 doi: 10.1007/s00259-020-04706-0
[75]
B. V. Jardim-Perassi, W. Mu, S. Huang, M. R. Tomaszewski, J. Poleszczuk, M. A. Abdalah, et al., Deep-learning and mr images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma, Theranostics, 11 (2021), 5313. https://doi.org/10.7150/thno.56595 doi: 10.7150/thno.56595
[76]
J. C. Forster, M. J. Douglass, W. M. Harriss-Phillips, E. Bezak, Development of an in silico stochastic 4D model of tumor growth with angiogenesis, Med. Phys., 44 (2017), 1563–1576.
[77]
W. M. Harriss-Phillips, E. Bezak, E. Yeoh, The HYP-RT hypoxic tumour radiotherapy algorithm and accelerated repopulation dose per fraction study, Comput. Math. Methods Med., 2012 (2012). https://doi.org/10.1155/2012/363564
This article has been cited by:
1.
Juan Margallo Iribarnegaray, Ricardo García Luján, Isabel Pina Maíquez, Fernando Revuelta Salgado, José Alfaro Abreu, Eduardo de Miguel Poch,
Montgomery T-Tube in the treatment of tracheal stenosis: Experience of a respiratory endoscopy unit and review of the literature,
2021,
57,
15792129,
72,
10.1016/j.arbr.2020.11.006
2.
Juan Margallo Iribarnegaray, Ricardo García Luján, Isabel Pina Maíquez, Fernando Revuelta Salgado, José Alfaro Abreu, Eduardo de Miguel Poch,
Prótesis en T de Montgomery para el tratamiento de la estenosis traqueal: experiencia de una Unidad de Endoscopia Respiratoria y revisión de la literatura,
2021,
57,
03002896,
70,
10.1016/j.arbres.2020.07.012
3.
Yuhua Fan, Xin Li, Xing Fang, Yalan Liu, Suping Zhao, Zicheng Yu, Yaoyun Tang, Ping Wu,
Antifibrotic Role of Nintedanib in Tracheal Stenosis After a Tracheal Wound,
2021,
131,
0023-852X,
10.1002/lary.29618
Chung-Kan Tsao, Hui-Yi Hsiao, Ming-Huei Cheng, Wen-Bin Zhong,
Tracheal Reconstruction with the Scaffolded Cartilage Sheets in an Orthotopic Animal Model,
2022,
28,
1937-3341,
685,
10.1089/ten.tea.2021.0193
6.
Adrien Ferney, Thibault Ferney, Ludovic Giraud, Amandine Briault, Marie-Pierre Aboussouan, Paul F. Castellanos, Ihab Atallah,
Endoscopic management of adult subglottic stenosis: an alternative to open surgery,
2023,
280,
0937-4477,
1865,
10.1007/s00405-022-07733-9
7.
Bengi Yilmaz, Bilge Yilmaz Kara,
Mathematical surface function-based design and 3D printing of airway stents,
2022,
8,
2365-6271,
10.1186/s41205-022-00154-8
8.
Fengjie Wu, Yangwei Yao, Yangyang Gu, Meng Yang, Enguo Chen, Huihui Hu, Jisong Zhang, Liangliang Dong, Yeli Zhu, Tao Huang,
Application of Montgomery T-Tube Placement in Treating Cotton-Myer IV Subglottic Airway Atresia after Bi-Level Airway Recanalization,
2021,
2021,
1748-6718,
1,
10.1155/2021/5517536
9.
Raviv Allon, Saurabh Bhardwaj, Josué Sznitman, Hagit Shoffel-Havakuk, Sapir Pinhas, Elchanan Zloczower, Yael Shapira-Galitz, Yonatan Lahav,
A Novel Trans-Tracheostomal Retrograde Inhalation Technique Increases Subglottic Drug Deposition Compared to Traditional Trans-Oral Inhalation,
2023,
15,
1999-4923,
903,
10.3390/pharmaceutics15030903
10.
Zhenyu Yang, Xiaoli Zhou, Wenying Pan, Daxiong Zeng, Junhong Jiang, Youfeng Zhu,
Clinical Analysis of 32 Cases of Subglottic Benign Airway Stenosis Treated With Montgomery T Silicone Stent,
2024,
2024,
1198-2241,
10.1155/2024/2145560
11.
Jinmei Wei, Shujuan Qin, Wentao Li, Yan Chen, Tingmei Feng, Yuhui Wei, Sen Tan, Guangnan Liu,
Analysis of clinical characteristics of 617 patients with benign airway stenosis,
2023,
10,
2296-858X,
10.3389/fmed.2023.1202309
12.
Yi-Ying Xiong, Chao-Yang Chen, Xiang Li, Xin-Xin Yue, Ze-Yu Zhao,
Efficacy of a self-made tracheostomy oxygen delivery device for oxygen therapy during postoperative anesthesia recovery,
2024,
09287329,
1,
10.3233/THC-241184
13.
Sen-Ei Shai, Yi-Ling Lai, Chi-Wei Hsieh, Shih-Chieh Hung,
A modified procedure of T-tube maneuver to treat tracheal total obstruction involving ablative bronchoscopy sparing open surgical intervention,
2023,
22,
26662507,
317,
10.1016/j.xjtc.2023.09.004
14.
Carina Escudero, Fernanda Chiarion Sassi, Ana Paula Ritto, Paulo Francisco Guerreiro Cardoso, Claudia Regina Furquim de Andrade,
Clinical and swallowing characteristics of tracheostomized patients with post-intubation acquired tracheal or laryngotracheal stenosis,
2025,
80,
18075932,
100552,
10.1016/j.clinsp.2024.100552
15.
Weifei Li, Yanjie Hu, Yan Hu, Meng Zhou, Yuehua Li, Jun Peng,
Relative Factors Analysis of the Occurrence and Location of Intratracheal Granuloma Following Tracheotomy,
2024,
Volume 17,
1178-7074,
6355,
10.2147/IJGM.S493335
16.
静 林,
Emergency Experience of Sudden Asphyxia Combined with Traditional Chinese Medicine Affective Care in a Patient with Benign Airway Stenosis after Balloon Dilatation and Tracheotomy,
2025,
14,
2168-5657,
209,
10.12677/ns.2025.142028
17.
XiaoFeng Liu, Lei Li, FuYao Nan, JiaPing Liu, Heng Zou, Nan Zhang, HongWu Wang,
Study on risk factors of Montgomery T-tube extraction in patients with post-tracheotomy tracheal stenosis based on Cox regression analysis,
2025,
25,
1471-2466,
10.1186/s12890-025-03732-8
Defne Yilmaz, Mert Tuzer, Mehmet Burcin Unlu. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach[J]. Mathematical Biosciences and Engineering, 2022, 19(11): 10941-10962. doi: 10.3934/mbe.2022511
Defne Yilmaz, Mert Tuzer, Mehmet Burcin Unlu. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach[J]. Mathematical Biosciences and Engineering, 2022, 19(11): 10941-10962. doi: 10.3934/mbe.2022511
Granulation tissue combined with tracheal wall collapse
1–2 cm
2
M
39
Craniocerebral trauma
9 months
Failed tracheal plugging
Complete
Granulation tissue
1–2 cm
3
F
55
Car accident trauma
6 months
Cough, Dyspnea
> 2/3
Granulation tissue combined with scar stenosis
2 cm
4
M
41
Cerebral hemorrhage
16 months
Cough, expectoration
> 2/3
Granulation tissue
1–2 cm
5
M
36
Cerebral hemorrhage
3 months
Dyspnea
Complete
Scar stenosis
2 cm
6
M
20
Electric injury
2 months
Expectoration, failed tracheal plugging
Complete
Scar stenosis
3 cm
7
M
46
Cerebral hemorrhage
20 days
Cough, expectoration, dyspnea
> 2/3
Tracheal distortions combined with scar stenosis
2–3 cm
8
M
66
Cerebral infarction
3 months
Failed tracheal plugging
Complete
Granulation tissue combined with scar stenosis
1–2 cm
9
M
52
Craniocerebral trauma
2 months
Cough, dyspnea
Complete
Granulation tissue combined with scar stenosis
1–2 cm
10
F
51
Cerebral hemorrhage
6 months
Failed tracheal plugging
> 2/3
Tracheal distortions combined with scar stenosis
1–2 cm
11
F
69
Cerebral hemorrhage
69 days
Failed tracheal plugging
> 2/3
Scar stenosis
1–2 cm
12
M
71
Cerebral hemorrhage
28 days
Failed tracheal plugging
Complete
Tracheal distortions combined with scar stenosis
1–2 cm
13
F
24
Granulomatosis with polyangiitis
36 days
Failed tracheal plugging
> 2/3
Granulation tissue combined scar stenosis
3 cm
14
M
66
Cerebral hemorrhage
3 months
Failed tracheal plugging
Complete
Tracheal distortions combined with scar stenosis
1–2 cm
15
F
55
Cerebral hemorrhage
50 days
Failed tracheal plugging
> 2/3
Scar stenosis
2 cm
16
F
47
Craniocerebral trauma
3 months
Failed tracheal plugging
> 2/3
Tracheal distortions combined with scar stenosis
2 cm
17
M
28
Craniocerebral trauma
2 months
Failed tracheal plugging
> 2/3
Granulation tissue combined with scar stenosis
3 cm
18
M
70
Cerebral infarction
1 months
Failed tracheal plugging
> 2/3
Scar stenosis
1–2 cm
19
M
48
Cerebral infarction
3 months
Failed tracheal plugging
Complete
Scar stenosis
> 3 cm
20
M
59
Cerebral hemorrhage
70 days
Failed tracheal plugging
> 2/3
Tracheal distortions combined with scar stenosis
2 cm
N: number; G: gender; M: male; F: female.
Cases
Rate
T-tube model (diameter mm)
13 mm: 3 14 mm: 5 15 mm: 3
8/20 9/20 3/20
Combined with balloon dilatation
18
18/20
Combined with rigid bronchoscopic mechanical expansion
13
13/20
Combined with granulation tissue resection
13
13/20
Retrograde tracheal blunt separation
8
8/20
Rate of postoperative tracheal plugging
19
19/20
Complications
Cases
Treatment measures and outcomes
Short-term < 24 h
Mediastinum / neck emphysema
1/20
Oxygen inhalation; self-absorbed after 3 d
Dyspnea
2/20
Improved after oxygen inhalation
Irritating cough
6/20
Not serious r; aerosol treatment
Increased secretion of mucous
20/20
Aerosol treatment of saline
Vocal cord edema
3/20
Untreated; improved after 24 h
Long-term * > 24 h
Obstruction due to mucous formation in T-tube
4/20
Suction under bronchoscope
Combined with lower respiratory tract infection
1/20
Improved after antibiotics treatment
Granulation tissue formed at proximal end of T-tube
13/20
Endoscopic granulation resection was performed in 5 cases
Granulation tissue formed at distal end of T-tube
0/20
—
T-tube re-implantation
3/20
Improved after T-tube re-implantation
Subcutaneous soft tissue infection
1/20
local disinfection and antibiotics therapy
Note: among the 20 cases, 18 patients had been completed 1-month follow-up, but 2 patients had not yet reached the 1-month follow-up date.
Figure 1. Tumor density for the control case. Tumor and vessel densities and oxygen levels for Days 19, 23 and 27
Figure 2. Treatment regimens for the various cases. The applied cases from top to bottom: only HAP application (Ⅰ), only chemotherapy drug application (Ⅱ), first HAP then chemotherapy drug application (Ⅲ), application of the HAP and chemotherapy drug at the same time (Ⅳ); the plots display the plasma concentrations of each drug over time
Figure 3. Total cell number for different cases. Resulting cell number for the cases of the control (Ⅰ), only HAP treatment (Ⅱ), only chemotherapy drug treatment (Ⅲ), HAP before chemotherapy (Ⅳ) and HAP combined with chemotherapy simultaneously (Ⅴ) by the end of the simulation. The combination of HAPs with chemotherapy resulted in more cell death than the untreated control or monotherapy cases
Figure 4. Total cell number and hypoxic area for different hypoxia levels. The changes in total cell number (a) and hypoxic area (b) for high, medium and low hypoxia levels before and after only HAP application. The cell numbers were calculated over time steps before and after the treatment, and the hypoxic area is expressed as a percentage of the total tumor area. The HAPs treatment reduced 68% of tumor cells under the high hypoxic condition while it killed only 27% of cells under the low hypoxic condition
Figure 5. Hypoxic area for different hypoxia levels. The changes in hypoxic area for high, medium and low hypoxia levels before and after the combination treatment. The hypoxic area is expressed as a percentage of the total tumor area